247
Participants
Start Date
March 3, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
MHS-1031
Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
Placebo
Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
ACTIVE_NOT_RECRUITING
University of Virginia Health System, Charlottesville
COMPLETED
Charlottesville Medical Research Center, Charlottesville
COMPLETED
GI Research Partners, LLC, Richmond
ACTIVE_NOT_RECRUITING
Digestive Disease and Liver Specialists, Norfolk
RECRUITING
M3 Wake Research (CPOR), Raleigh
ACTIVE_NOT_RECRUITING
WR-Mount Vernon Clinical Research (MVCR), Sandy Springs
COMPLETED
EmVenio-Georgia (EMGA), Atlanta
RECRUITING
Wr-Msra, Llc, Lake City
RECRUITING
A Positive Clinical Research, Miami
ACTIVE_NOT_RECRUITING
Health Synergy Clinical Research, West Palm Beach
TERMINATED
West Palm Quality Research (WPQR), West Palm Beach
RECRUITING
Advanced Gastroenterology Associates LLC, Palm Harbor
ACTIVE_NOT_RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Gastroenterology Associates of Western Michigan PLC (WMCR), Wyoming
RECRUITING
SMS Clinical Research (SMSR), Mesquite
ACTIVE_NOT_RECRUITING
A and U Family Medicine (NCR), Sugar Land
RECRUITING
Elite Clinical Studies LLC, Phoenix
Lead Sponsor
VBHRC Virginia Catalyst
UNKNOWN
Microbiome Health Sciences
INDUSTRY